Entrada Therapeutics, Inc.
TRDA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $25.4M | $211M | −87.9% |
| Operating income | −$158M | $47.0M | |
| Net income | −$144M | $65.6M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $900K | $1.60M | −43.8% |
| Operating income | −$41.7M | −$47.1M | +11.5% |
| Net income | −$39.7M | −$44.1M | +10.0% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Entrada Therapeutics's revenue in FY2025?
- $25.4M in FY2025 (Fiscal year ended Dec 31, 2025), −87.9% vs $211M a year earlier, per its 10-K filed Feb 2026.
- Was Entrada Therapeutics profitable in FY2025?
- No: net income was −$144M and operating income −$158M in FY2025.
- What was Entrada Therapeutics's revenue in Q3 2026?
- $900K (−43.8% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.